Recombinant SARS-CoV-2 Nucleocapsid Protein NTD, His Tag (MALS verified), 100µg

Background
Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.

Source
Recombinant SARS-CoV-2 Nucleocapsid Protein NTD, His Tag (NUN-C5143) is expressed from E.coli cells. It contains AA Gly 44 - Glu 174 (Accession # QHO62115.1).
Predicted N-terminus: Met 1

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 15.3 kDa. The protein migrates as 16 kDa under reducing (R) condition (SDS-PAGE).

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Molecular elucidation of drug-induced abnormal assemblies of the hepatitis B virus capsid protein by solid-state NMR"
Lecoq, Brigandat, Huber et al
Nat Commun (2023) 14 (1), 471
(2) "Energetic and frustration analysis of SARS-CoV-2 nucleocapsid protein mutations"
Haque, Khatoon, Ashgar et al
Biotechnol Genet Eng Rev (2023)
(3) "In silico design of a multi-epitope vaccine against the spike and the nucleocapsid proteins of the Omicron variant of SARS-CoV-2"
Bayani, Safaei Hashkavaei, Karamian et al
J Biomol Struct Dyn (2023)
Showing 1-3 of 53660 papers.